{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.28","value":"12.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"}],"units":"Participants"}],"description":"CL/F is defined as apparent oral clearance.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with FGFR2 rearrangements or fusions (Cohort A), participants with all other FGF/FGFR alterations (Cohort B), participants with no FGF/FGFR alterations (Cohort C; United States only), and participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally (Other) self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG000","title":"All Cohorts"}],"paramType":"MEAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Predose; 1-2 hours post-dose; 4-12 hours post-dose","title":"CL/F of Pemigatinib","type":"SECONDARY","unitOfMeasure":"Liters/hour"}